Hasil Pencarian - Arjun V Balar

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience

    Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience oleh Michael Crist, Gopa Iyer, Miles Hsu, William C. Huang, Arjun V. Balar

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report

    A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report oleh Ezra Bernstein, James Weinberger, Avi Baskin, Eesha Balar, Victor Adorno Febles, Arjun V. Balar

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy

    Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy oleh Michael Lattanzi, Fang-Ming Deng, Luis A. Chiriboga, Alisa N. Femia, Shane A. Meehan, Gopa Iyer, Martin H. Voss, Yuliya Sundatova, William C. Huang, Arjun V. Balar

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

    BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma oleh Brian W. Labadie, Ping Liu, Riyue Bao, Michael Crist, Ricardo Fernandes, Laura Ferreira, Scott Graupner, Andrew S. Poklepovic, Ignacio Duran, Saman Maleki Vareki, Arjun V. Balar, Jason J. Luke

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

    Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival oleh Guilhem Richard, Anne S. De Groot, Gary D. Steinberg, Tzintzuni I. Garcia, Alec Kacew, Matthew Ardito, William D. Martin, Gad Berdugo, Michael F. Princiotta, Arjun V. Balar, Randy F. Sweis

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

    Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study oleh Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar, Ronald de Wit

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer oleh Gary D Steinberg, Neal Shore, Petros Grivas, Matthew D Galsky, Elizabeth R Plimack, Shilpa Gupta, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks, Jonathan E Rosenberg, Ashish M Kamat

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

    Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study oleh Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

    Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy oleh Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: